Preferred Label : Zirconium Zr 89 Crefmirlimab Berdoxam;
NCIt synonyms : 89Zr-Desferrioxamine-IAB22M2C; 89Zr-Df-IAB22M2C; Zirconium Zr 89-Df-IAB22M2C; 89Zr-Df-Crefmirlimab; 89Zr-Crefmirlimab Berdoxam; Zirconium Zr 89-Df-Crefmirlimab;
NCIt related terms : ZIRCONIUM ZR-89 CREFMIRLIMAB BERDOXAM;
NCIt definition : A radioimmunoconjugate comprised of a minibody (Mb), an inert antibody fragment against
the human CD8-antigen on CD8-positive T-cells, conjugated to the chelator desferrioxamine
(Df) and labeled with the radioisotope zirconium Zr 89, with potential positron emission
tomography (PET) imaging activity. Upon administration, zirconium Zr 89 crefmirlimab
berdoxam specifically targets and binds to the CD8 antigen expressed on T-cells. This
enables PET detection of the radioisotope moiety, and may allow the imaging, tracking
and quantification of CD8-expressing T-cells. This may detect CD8-positive T-cell
distribution and activity, and may help determine the patient's response to cancer
immunotherapeutic agents. CD8-positive T-cells play a key role in the eradication
of cancer cells. Although the Mb has the same antigen specificity and binding affinity
as the full-length antibody, the Mb does not activate or induce the proliferation
of CD8-positive T-cells.;
UNII : J6AJI0OZ1O;
CAS number : 2377668-38-5;
NCI Metathesaurus CUI : CL524896;
Origin ID : C137822;
UMLS CUI : C4527230;
Semantic type(s)
- concept_is_in_subset
- has_target
